(Q36398660)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16483260%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

review article

1 reference

title

Therapeutic intervention in the GLP-1 pathway in Type 2 diabetes (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16483260%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

1 reference

Jonathan Cummings Levy

series ordinal

1

object named as

J C Levy

2 references

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16483260%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

14 August 2017

publication date

1 March 2006

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16483260%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16483260%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

volume

23 Suppl 1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16483260%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

page(s)

14-19

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16483260%20AND%20SRC:MED&resulttype=core&format=json

Potential therapies mimicking the effects of glucagon-like peptide-1 for the treatment of type 2 diabetes

16 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2006.01833E.X

Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and beta-cell function in type 2 diabetes: a parallel-group study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2006.01833E.X

A meta-analysis of the effect of glucagon-like peptide-1 (7-36) amide on ad libitum energy intake in humans.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2006.01833E.X

Glucagon-like peptide-1 and the islet beta-cell: augmentation of cell proliferation and inhibition of apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2006.01833E.X

Inhibition of dipeptidyl peptidase-4 reduces glycemia, sustains insulin levels, and reduces glucagon levels in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2006.01833E.X

Vildagliptin, a dipeptidyl peptidase-IV inhibitor, improves model-assessed beta-cell function in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2006.01833E.X

(2R)-4-oxo-4-[3-(trifluoromethyl)-5,6-dihydro[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl]-1-(2,4,5-trifluorophenyl)butan-2-amine: a potent, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2006.01833E.X

Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2006.01833E.X

Effectiveness of progressive dose-escalation of exenatide (exendin-4) in reducing dose-limiting side effects in subjects with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2006.01833E.X

10.1111/J.1464-5491.2006.01833E.X

21 January 2018

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16483260%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

1 reference